We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Interest in Commercial Applications for Proteomics Continues to Grow

By LabMedica International staff writers
Posted on 15 Oct 2014
Print article
Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies.

Proteomics is the study of the structure and function of proteins. This includes the study of which proteins are expressed, when and where they are expressed, and of interactions with proteins and other types of molecules. Many drug targets are proteins, and proteomics is an important tool for identification and characterization of novel drug targets. Furthermore, proteomics is an important tool for the identification of novel biomarkers and biomarker panels for diagnosis of diseases.

Among the significant business connections cited in the recent report “Proteomics Markets for Research and IVD Applications” published by Kalorama Information (New York, NY, USA) were:

Thermo Fisher Scientific (Milford, MA, USA) and Nuclea Biotechnologies (Pittsfield, MA, USA) will develop multiplexed mass spectrometry-based research methods that Nuclea will use to analyze donor plasma samples from Boston-based diabetes research collaborations.

BG Medicine (Waltham, MA, USA) and Kindstar Diagnostics (China) announced an agreement under which Kindstar will offer galectin-3 testing services in China.

Biocartis (Mechelen, Belgium) and Invetech (Melbourne (Australia) announced a collaboration agreement to support development and manufacture of Evalution, Biocartis’ advanced multiplex platform for analysis of a broad range of protein and nucleic acid-based biomarkers. Invetech provides instrument development, custom automation, and contract manufacturing.

“There is a lot of interest in identification and validation of novel biomarkers that may represent potential drug targets or may lead to novel diagnostic tests,” said Bruce Carlson, publisher of Kalorama Information. “Researchers are looking to proteomics for these discoveries.”

Related Links:

Kalorama Information


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Ultrasound-based duplex sonography combined with a new genetic testing procedure can identify clonal haematopoiesis (Photo courtesy of 123RF)

New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk

A key interest area in cardiovascular research today is the impact of clonal hematopoiesis on cardiovascular diseases. Clonal hematopoiesis results from mutations in hematopoietic stem cells and may lead... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.